They are indicated for adults with relapsing forms of MS. In the end, starting and sticking to a DMT—even if you have to ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

He cited data that show about 40% of patients with MS aged older than 60 years in the United States still use DMT. Peak use occurs between age 41 to 50 years. Corboy reviewed data from the DISCOMS ...

Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

Dr Annalisa Morgan reflects on incorporating new treatments discussed at the 2025 ACTRIMS Forum into clinical practice.

“Comorbidities are common in persons with MS, but comorbidity status is not generally reported in [disease-modifying therapy (DMT)] trials,” Amber Salter, PhD, associate professor of ...

Be sure to carefully discuss with your MS healthcare provider whether the potential benefits of the DMT you are considering ...

Biogen’s commitment to MS management extends beyond understanding the pathogenic role of CNS-targeted autoimmunity and traditional DMT research to fostering innovative treatment initiatives ...